Peripheral neuropathy, a complex and multifaceted disorder, presents a diagnostic challenge in clinical practice due to its myriad etiologies and presentations. A comprehensive approach to evaluation and diagnosis is essential to ensure optimal patient outcomes.
Peripheral neuropathy may arise from systemic illnesses, infections, toxins, or genetic disorders. A thorough patient history and physical examination, including a detailed neurological examination, are the first steps in identifying potential causes. Laboratory investigations should be guided by the findings of the history and examination, focusing on ruling out common causes such as diabetes, vitamin deficiencies, and renal or liver diseases.
Electrodiagnostic studies, including nerve conduction studies and electromyography, are essential tools in the diagnosis of peripheral neuropathy. These tests help in determining the extent of nerve damage, the type of neuropathy (axonal or demyelinating), and the distribution (mononeuropathy or polyneuropathy).
Quantitative sensory testing, autonomic testing, and skin biopsies can provide further diagnostic insights. They can help distinguish between small and large fiber neuropathies, assess the severity of neuropathic pain, and detect autonomic involvement.
For patients with a family history suggestive of hereditary neuropathy or those with no identifiable cause after initial evaluation, genetic testing can be considered. It can identify pathogenic variants associated with hereditary neuropathies, providing definitive diagnosis and guiding management.
Diagnosing peripheral neuropathy requires a comprehensive approach that includes a thorough history, physical examination, appropriate laboratory investigations, neurophysiological testing, and, in some cases, genetic testing. This approach enables accurate diagnosis, guides treatment, and improves patient outcomes.
1.
Regular physical activity before cancer diagnosis may lower progression and death risks
2.
Medication Self-Injection Embraced by Breast Cancer Patients
3.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
4.
FDA Advisors Split on Regimens for Breast, Prostate Cancers
5.
ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs
1.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
2.
Clinical Pathways in Hematology in Clinical Decision-Making
3.
Immune Surveillance Screening for Early Cancer Risk Detection
4.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
5.
AI-Driven Digital Pathology in Oncology: From Histology Images to Predictive Treatment Biomarkers
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
How Advances in Cancer Research Are Improving Treatment Options
2.
Navigating the Complexities of Ph Negative ALL - Part II
3.
Signs and Symptoms of Leukemia
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation